全文获取类型
收费全文 | 1291篇 |
免费 | 107篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 51篇 |
妇产科学 | 20篇 |
基础医学 | 235篇 |
口腔科学 | 26篇 |
临床医学 | 105篇 |
内科学 | 258篇 |
皮肤病学 | 12篇 |
神经病学 | 152篇 |
特种医学 | 35篇 |
外科学 | 137篇 |
综合类 | 4篇 |
预防医学 | 173篇 |
眼科学 | 7篇 |
药学 | 53篇 |
肿瘤学 | 132篇 |
出版年
2024年 | 3篇 |
2023年 | 36篇 |
2022年 | 65篇 |
2021年 | 98篇 |
2020年 | 71篇 |
2019年 | 65篇 |
2018年 | 91篇 |
2017年 | 41篇 |
2016年 | 63篇 |
2015年 | 61篇 |
2014年 | 55篇 |
2013年 | 76篇 |
2012年 | 101篇 |
2011年 | 97篇 |
2010年 | 61篇 |
2009年 | 47篇 |
2008年 | 52篇 |
2007年 | 56篇 |
2006年 | 52篇 |
2005年 | 36篇 |
2004年 | 33篇 |
2003年 | 36篇 |
2002年 | 21篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 13篇 |
1998年 | 6篇 |
1997年 | 4篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1989年 | 3篇 |
1987年 | 5篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1947年 | 1篇 |
1942年 | 1篇 |
1939年 | 2篇 |
1938年 | 1篇 |
1935年 | 1篇 |
1933年 | 2篇 |
1932年 | 1篇 |
1930年 | 1篇 |
1925年 | 2篇 |
1920年 | 1篇 |
1918年 | 1篇 |
1914年 | 1篇 |
1912年 | 1篇 |
1911年 | 1篇 |
1910年 | 2篇 |
1904年 | 1篇 |
排序方式: 共有1406条查询结果,搜索用时 0 毫秒
1.
Histologic distinction between malignant mesothelioma,benign pleural lesion and carcinoma metastasis
W. S. Kwee R. W. Veldhuizen R. P. Golding H. Mullink J. Stam R. Donner Mathilde E. Boon 《Virchows Archiv : an international journal of pathology》1982,397(3):287-299
Summary Thirty men and 7 women with malignant mesothelioma seen at the Free University Hospital from 1st January 1960 until 1st July 1981 were reviewed.The histological, histochemical and morphometrical findings are reported. These findings are compared with 25 cases of pleural metastatic carcinoma and 25 cases of reactive pleural lesions.Fourty-nine percent of malignant mesotheliomas produced hyaluronic acid, however all cases of pleural metastatic carcinomas failed to produce this substance. All cases of malignant mesothelioma were D-PAS negative while 15 cases of pleural metastatic carcinoma showed reactivity to D-PAS. All cases of malignant mesothelioma and 9 cases of metastases were CEA negative.To distinguish malignant mesothelioma from metastases it is advisable to perform the D-PAS staining first. If it is negative mesothelioma can be confirmed by showing hyaluronic acid activity. A positive CEA staining rules out mesothelioma. In our study it was shown that with these methods 18 of 37 mesotheliomas could be identified with certainty, and 22 of the 25 carcinoma metastases.Morphometrically the malignant mesotheliomas could not be distinguished from the metastases, however the reactive pleural lesions had smaller nuclei than the malignant cells with mean values below 30 mu2. In the malignant cases these values had a range from 36 to 101 mu2.In distinguishing between reactive pleural lesions and malignant mesothelioma the production of hyaluronic acid points to the malignant character of the lesion.Thus histochemistry and immunostaining are important in the distinction of malignant mesothelioma from metastases, while the value of morphometry lies mainly in the separation of reactive lesions from malignant mesothelioma. 相似文献
2.
3.
Anja C. M. de Bruin Mathis Funk Monique I. Spronken Alexander P. Gultyaev Ron A. M. Fouchier Mathilde Richard 《Viruses》2022,14(7)
Highly Pathogenic Avian Influenza Viruses (HPAIVs) arise from low pathogenic precursors following spillover from wild waterfowl into poultry populations. The main virulence determinant of HPAIVs is the presence of a multi-basic cleavage site (MBCS) in the hemagglutinin (HA) glycoprotein. The MBCS allows for HA cleavage and, consequently, activation by ubiquitous proteases, which results in systemic dissemination in terrestrial poultry. Since 1959, 51 independent MBCS acquisition events have been documented, virtually all in HA from the H5 and H7 subtypes. In the present article, data from natural LPAIV to HPAIV conversions and experimental in vitro and in vivo studies were reviewed in order to compile recent advances in understanding HA cleavage efficiency, protease usage, and MBCS acquisition mechanisms. Finally, recent hypotheses that might explain the unique predisposition of the H5 and H7 HA sequences to obtain an MBCS in nature are discussed. 相似文献
4.
Fievet P Coppin M Brazier F Lefèvre M Stephan R Demontis R 《Néphrologie & thérapeutique》2012,8(1):41-46
Anemia is a common complication of chronic kidney disease (CKD) in predialysis stage. Iron deficiency is more common than in normal patients and plays a key role in the genesis of anemia. Its correction avoids the use of erythropoiesis stimulating agents (ESA) or reduces their dosage. Treatment with oral iron is often poorly tolerated and ineffective, necessitating the use of intravenous iron. New forms of injectable iron allow the use of high doses and correct iron deficiency in a single administration with consequent preservation of venous capital and lower costs. We studied the effectiveness of iron dextran of low molecular weight (LMWID) in high doses to correct iron deficiency and treat anemia in predialysis CKD patients. Twenty-nine doses of 500 to 1600 mg were administered to 25 patients followed for CKD (GFR between 60 and 10 ml/min per 1.73 m2), selected on biological criteria of iron deficiency defined by a ratio of transferrin saturation (TSAT) < 20% and/or serum ferritin of less than 100 μg/L. Patients received treatment by ESA in 16 cases out of 29. One month after treatment, hemoglobin (Hb) increased significantly (11.4 ± 1.6 vs 10.4 ± 1.4 g/dL, P = 0.0003) along with a significant increase in TSAT (21.3 ± 7.3 vs 13.3 ± 3.8%, P = 0.000003) and serum ferritin (286 ± 253 vs 91 ± 60 μg/L, P = 0.00005). Six patients had a serum ferritin greater than 500 μg/L after treatment, which may put them at risk of iron overload. Their serum ferritin was higher than the rest of the population before treatment, while the TSAT was no different, reflecting a functional deficiency. Their hemoglobin did not increase after treatment in contrast to the rest of the population suggesting the unavailability of iron for erythropoiesis with accumulation in the reticuloendothelial system. Renal function did not change significantly and there were no cases of acute renal failure. No immediate side effect was observed. Three patients presented delayed reactions to such self-limiting myalgia and arthralgia. No venous inflammatory reaction was noted. The administration of high doses of LMWID is effective in treating anemia of CKD in the predialysis stage with a satisfactory tolerance, without affecting kidney function and helps preserve the venous capital. It should be reserved for patients whose serum ferritin is less than or equal to 150 μg/L. 相似文献
5.
Wnuk M Hlushchuk R Janot M Tuffin G Martiny-Baron G Holzer P Imbach-Weese P Djonov V Huynh-Do U 《Kidney international》2012,81(12):1212-1225
Eph receptor tyrosine kinases and their ligands (ephrins) have a pivotal role in the homeostasis of many adult organs and are widely expressed in the kidney. Glomerular diseases beginning with mesangiolysis can recover, with podocytes having a critical role in this healing process. We studied here the role of Eph signaling in glomerular disease recovery following mesangiolytic Thy1.1 nephritis in rats. EphB4 and ephrinBs were expressed in healthy glomerular podocytes and were upregulated during Thy1.1 nephritis, with EphB4 strongly phosphorylated around day 9. Treatment with NPV-BHG712, an inhibitor of EphB4 phosphorylation, did not cause glomerular changes in control animals. Nephritic animals treated with vehicle did not have morphological evidence of podocyte injury or loss; however, application of this inhibitor to nephritic rats induced glomerular microaneurysms, podocyte damage, and loss. Prolonged NPV-BHG712 treatment resulted in increased albuminuria and dysregulated mesangial recovery. Additionally, NPV-BHG712 inhibited capillary repair by intussusceptive angiogenesis (an alternative to sprouting angiogenesis), indicating a previously unrecognized role of podocytes in regulating intussusceptive vessel splitting. Thus, our results identify EphB4 signaling as a pathway allowing podocytes to survive transient capillary collapse during glomerular disease. 相似文献
6.
Niaudet P Charbit M Loirat C Lapeyraque AL Tsimaratos M Cailliez M Foulard M Dehennault M Marquet P Chaouche-Teyara K Lemay D 《Pediatric nephrology (Berlin, Germany)》2009,24(2):395-402
Data on the use of enteric-coated mycophenolic acid (EC-MPS) in pediatric transplantation cases are scarce. We undertook a
12-month, multicenter, open-label pilot study in which 16 de novo renal transplant patients aged 5–16 years received EC-MPS
with cyclosporine A microemulsion (CsA-ME), steroids, and anti-interleukin-2 receptor antibody induction. The mean dose of
EC-MPS was 916 ± 93 mg/m2 per day during weeks 1–2, 810 ± 193 mg/m2 per day during months 3–6, and 827 ± 153 mg/m2 per day during months 6–12. The mean CsA C2 level exceeded target range up to month 6 post-transplant. Efficacy failure (biopsy-proven acute rejection, graft loss, death
or loss to follow-up) occurred in two patients: one patient with primary non-function underwent nephrectomy, and one patient
experienced biopsy-proven acute rejection (Grade 1B, day 344) following EC-MPS dose reduction. There were no deaths. Creatinine
clearance (Schwartz) was 103 ± 30 mL/min per 1.73 m2 at month 6 and 100 ± 16 mL/min per 1.73 m2 at month 12. The majority of adverse events were mild or moderate (101/126, 80.2%). In this pilot study, EC-MPS 450 mg/m2 administered twice daily with CsA, steroids, and interleukin-2 antibody induction resulted in a low rate of rejection with
good renal function in a pediatric population. However, a larger, controlled trial is required to confirm these results. 相似文献
7.
Antoine Sicard Caroline Lamarche Madeleine Speck May Wong Isaac Rosado‐Snchez Mathilde Blois Nicolas Glaichenhaus Majid Mojibian Megan K. Levings 《American journal of transplantation》2020,20(6):1562-1573
Cell therapy with autologous donor‐specific regulatory T cells (Tregs) is a promising strategy to minimize immunosuppression in transplant recipients. Chimeric antigen receptor (CAR) technology has recently been used successfully to generate donor‐specific Tregs and overcome the limitations of enrichment protocols based on repetitive stimulations with alloantigens. However, the ability of CAR‐Treg therapy to control alloreactivity in immunocompetent recipients is unknown. We first analyzed the effect of donor‐specific CAR Tregs on alloreactivity in naive, immunocompetent mice receiving skin allografts. Tregs expressing an irrelevant or anti‐HLA‐A2‐specific CAR were administered to Bl/6 mice at the time of transplanting an HLA‐A2+ Bl/6 skin graft. Donor‐specific CAR‐Tregs, but not irrelevant‐CAR Tregs, significantly delayed skin rejection and diminished donor‐specific antibodies (DSAs) and frequencies of DSA‐secreting B cells. Donor‐specific CAR‐Treg–treated mice also had a weaker recall DSA response, but normal responses to an irrelevant antigen, demonstrating antigen‐specific suppression. When donor‐specific CAR Tregs were tested in HLA‐A2‐sensitized mice, they were unable to delay allograft rejection or diminish DSAs. The finding that donor‐specific CAR‐Tregs restrain de novo but not memory alloreactivity has important implications for their use as an adoptive cell therapy in transplantation. 相似文献
8.
9.
10.
Tarver Joanne Vitoratou Silia Mastroianni Mathilde Heaney Natalie Bennett Eleanor Gibbons Felicity Fiori Federico Absoud Michael Ramasubramanian Lakshmi Simonoff Emily Santosh Paramala 《Journal of autism and developmental disorders》2021,51(8):2812-2828
Journal of Autism and Developmental Disorders - Although 70% of autistic children and young people meet criteria for co-occurring psychiatric conditions, there are few screening measures... 相似文献